DURECT (NASDAQ:DRRX) Coverage Initiated at StockNews.com
StockNews.com began coverage on shares of DURECT (NASDAQ:DRRX – Free Report) in a research report report published on Tuesday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock. Separately, HC Wainwright restated a “neutral” rating on shares of DURECT in a research report on Thursday, November 14th. Get Our Latest Stock Analysis […]
StockNews.com began coverage on shares of DURECT (NASDAQ:DRRX – Free Report) in a research report report published on Tuesday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock. Separately, HC Wainwright restated a “neutral” rating on shares of DURECT in a research report on Thursday, November 14th. Get Our Latest Stock Analysis […]
